An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Two diabetes drugs have been in the headlines because they help lower blood sugar and often cause weight loss, and people ask which one is different or better. The short version: dulaglutide and semaglutide are two prescription medicines that act in similar ways but have some practical differences in dosing, how strong they tend to be for weight loss, and how they are given. Both are approved by regulators for treating type 2 diabetes; semaglutide also has formulations specifically approved for weight loss. Both drugs are members of a class that mimics a natural gut hormone called GLP-1 (that stands for glucagon-like peptide-1). That hormone tells your body to release insulin when you eat, slows how fast your stomach empties so you feel full longer, and reduces appetite. Saying a drug is a “GLP-1 receptor agonist” just means it fits into the same receptor (the cell’s lock) as the natural hormone (the key) and turns on similar signals. Semaglutide and dulaglutide are engineered versions that last longer in the body than the natural hormone so they can be dosed weekly. What the research shows is mostly from clinical trials in people with type 2 diabetes and separate trials for weight loss. Semaglutide has generally produced larger average weight loss compared with dulaglutide in head-to-head studies and in separate trials — often by several percentage points of body weight. Both lower blood sugar well, but semaglutide tends to reduce A1c (a long-term blood sugar measure) a bit more in many studies. These findings come from randomized clinical trials with hundreds to thousands of participants and from regulatory reviews, not from small anecdotes. However, individual results vary and not every person will get the same benefit. Why this matters is practical. If you have type 2 diabetes and your main goal is improving blood sugar, both drugs are good options and your clinician will consider other factors like heart benefits, kidney effects, side effects, cost and insurance coverage. If weight loss is the main goal, semaglutide (or its higher-dose brand for obesity) tends to be the stronger choice based on trial results. There are also convenience differences: both are typically injected once weekly, but the injection device, dose escalation schedules, and available strengths differ, which can affect comfort and adherence. Caveats: neither drug is a magic solution and both carry side effects. Common ones are nausea, vomiting, diarrhea, and constipation, especially when starting or increasing the dose. Rare but serious risks include pancreatitis (inflammation of the pancreas) and possible gallbladder problems; there are also safety questions about thyroid tumors seen in animal studies that are being watched in humans. These drugs are prescription-only; semaglutide is available in formulations under different brand names for diabetes and for weight loss, and dulaglutide is approved for diabetes. Insurance coverage and cost vary a lot. People with a personal or family history of certain thyroid cancers or with a history of pancreatitis should discuss risks carefully with their doctor. Bottom line: both drugs work by copying a natural appetite and blood-sugar hormone, semaglutide usually produces bigger weight loss and slightly stronger blood-sugar drops in trials, but the right choice depends on your health goals, side effects, cost and a clinician’s judgment.
Source: Forbes